Skip to main content
. Author manuscript; available in PMC: 2013 Sep 8.
Published in final edited form as: Clin Gastroenterol Hepatol. 2008 Nov 7;7(2):219–226. doi: 10.1016/j.cgh.2008.10.034

Figure 2.

Figure 2

Serum fibrosis marker levels before, during and after 48 weeks of pegylated interferon and ribavirin treatment. (□ = Sustained virological responders; ▲ = Breakthru/relapsers). A). Log10 YKL-40 levels were significantly lower at week 72 compared to baseline in the SVR patients (p=0.0002) and remained unchanged in the breakthrough/relapsers B). Log10 hyaluronic acid levels were significantly lower at week 72 in the SVR patients (p < 0.0001) as well as the breakthrough/relapsers compared to week 0 (p= 0.007). C). Serum PIIINP levels significantly declined at week 72 compared to week 0 in the SVR patients (p = 0.0004) but were unchanged in the breakthrough/relapsers (p= 0.21) D). Serum TIMP-1 levels only significantly declined at week 72 compared to baseline in the SVR patients (p=0.0022).